Shots:

• The P-III VICTORIA study involves assessing of Vericiguat vs PBO in combination with available HF therapies in 5-050 patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) following a decompensation event across 600 centers in 42 countries
• The P-III VICTORIA study resulted in meeting its 1EPs i.e- reduction in heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with HFrEF
• Vericiguat is an investigational soluble guanylate cyclase (sGC) stimulator- jointly developed by Merck and Bayer. In Oct’2014- Bayer and Merck entered into a WW collaboration to develop sGC modulators

Click here to­ read full press release/ article 

Ref: Merck | Image: Merck